Recent Updates
Recently added Catalysts

Mesalamine

Phase 4FDA approved

Undisclosed | Small molecule | Other |Takeda Pharmaceutical Company Limited|Trials Updated: Jun 23, 2021

Mesalamine development status

FDA approval on record Jan 5, 2001
Approval holderAbbvie
ApplicationNDA021252
Highest phase Phase 4 (NCT00446849)
Phase scored for TAKPhase 1
Registered trials 13 across 8 sponsors since Sep 2005

Label indication CANASA is indicated in adults for the treatment of mildly to moderately active ulcerative proctitis. CANASA is an aminosalicylate indicated in adults for the treatment of mildly to moderately active ulcerative proctitis. ( 1 ) FDA label

Mesalamine target and mechanism

Molecular targetALOX5, PTGS2, PTGS1, PPARG
Target classInhibitor
ModalitySmall molecule
ChEMBLCHEMBL704

Also known as SPD476, Lialda, mesalazine, MMX mesalamine, Asacol

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials7
Total Enrollment2,588

FDA Designations

No designations recorded

Mesalamine clinical trials

Mesalamine · 7 trials · 4 indications

Phase 3 5Phase 1 2
NCT02093663Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative ColitisUlcerative Colitis
COMPLETED107 Analytics
NCT00545103Prevention of Recurrence of DiverticulitisDiverticulitis
COMPLETED592 Analytics
NCT00545740Prevention of Recurrence of DiverticulitisDiverticulitis
COMPLETED590 Analytics
NCT00151892Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative ColitisUlcerative Colitis
COMPLETED829 Analytics
NCT00151944Safety and Tolerability of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis.Colitis, Ulcerative
COMPLETED400 Analytics
PHASE3COMPLETED
Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis
Ulcerative ColitisUnlock trial analytics
PHASE3COMPLETED
Prevention of Recurrence of Diverticulitis
DiverticulitisUnlock trial analytics
PHASE3COMPLETED
Prevention of Recurrence of Diverticulitis
DiverticulitisUnlock trial analytics
PHASE3COMPLETED
Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis
Ulcerative ColitisUnlock trial analytics
PHASE3COMPLETED
Safety and Tolerability of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis.
Colitis, UlcerativeUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Clinical Response During Double-Blind Acute Phase at Week 8
Week 8

Clinical response was defined as partial ulcerative colitis disease activity index (UC-DAI) score \< or =1 with rectal bleeding = 0, stool frequency \< or =1, and physician's global assessment (PGA = 0). Number of participants with clinical response were reported.

Number of Participants With Clinical Response During Double-blind Maintenance Phase at Week 26
Week 26

Clinical response was defined as partial UC-DAI \<=1 with (rectal bleeding = 0, stool frequency \< or =1, and PGA = 0). Number of participants who had maintained clinical response were reported.

Percent of Subjects Without Recurrence of Diverticulitis
up to 104 Weeks

Recurrence of diverticulitis is defined as the presence of each and all of the following 3 items: 1) abdominal pain, 2) a 15% increase in white blood cell count from baseline, 3) bowel wall thickening (\>5 mm) and/or fat stranding as evidenced by spiral computerized axial tomography (CT) scan; OR surgical intervention for diverticular disease. Withdrawals are considered as recurrences.

Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months
6 Months

Endoscopic remission is defined as an endoscopy score of less than or equal to 1. Endoscopy score (mucosal appearance) ranges from 0-3 (0 = normal \[intact vascular pattern; no friability or granulation\], 1 = mild \[erythema; decreased vascular pattern; minimal granularity\], 2 = moderate \[marked erythema; granularity; friability; absent vascular pattern; bleeding with minimal trauma; no ulcerations\], 3 = severe \[ulceration; spontaneous bleeding\].

Treatment emergent adverse events
Throughout the study period of approximately 2 year, 4 months
Number of Participants With Positive Responses to Palatability Assessment of The Taste of Mesalamine
Immediately post-dose

A taste assessment was completed immediately after investigational product was administered to assess the subject's taste/liking of the formulation. The assessment consisted of a 5-point rating scale. Participants were asked to choose one of the following responses to the statement "The taste was acceptable": strongly agree, agree, neutral, disagree, or strongly disagree. The number of participants who chose either of the top two responses (strongly agree, agree) is reported.

Number of Participants Who Detected an Aftertaste of Mesalamine
5 minutes post-dose

An aftertaste assessment was completed 5 minutes after administration of investigational product to assess whether the participants detected an aftertaste. The participants answered "Yes" or "No" to the following question: "Was there an aftertaste?" The number of participants who answered "Yes" is reported.

Number of Participants With Positive Responses to Palatability Assessment of The Aftertaste of Mesalamine
5 minutes post-dose

An aftertaste assessment was completed 5 minutes after administration of investigational product to assess the subject's rating of aftertaste and means of administration. The assessment consisted of a 5-point rating scale. The participants were asked to choose one of the following responses to the statement "The aftertaste (if present) was acceptable": strongly agree, agree, neutral, disagree, or strongly disagree. The number of participants who chose either of the top two responses (strongly agree, agree) is reported.

Number of Participants Willing to Take Mesalamine Via Treatment Method on a Regular Basis
Immediately post-dose

The participants were asked to answer "Yes" or "No" to the following question: "Would you be willing to take medicine this way on a regular basis if necessary?" The number of participants who answered "Yes" is reported.

Area Under the Plasma Concentration Versus Time Curve (AUC) of MMX Mesalamine (5-ASA) at Steady State
2, 4, 6, 9, 12, 16, and 24 hours post-dose on day 7

AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

Maximum Plasma Concentration (Cmax) of MMX Mesalamine (5-ASA) at Steady State
Over a 24-hour period starting on day 7

Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.

Time to Maximum Plasma Concentration (Tmax) of MMX Mesalamine (5-ASA) at Steady State
Over a 24-hour period starting on day 7

Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.

Total Body Clearance (CL) of MMX Mesalamine (5-ASA) at Steady State
Over a 24-hour period starting on day 7

Clearance of a substance from the blood by the kidneys.

AUC of MMX Mesalamine Major Metabolite (Ac-5-ASA) at Steady State
2, 4, 6, 9, 12, 16, and 24 hours post-dose on day 7
Cmax of MMX Mesalamine Major Metabolite (Ac-5-ASA) at Steady State
Over a 24-hour period starting on day 7
Tmax of MMX Mesalamine Major Metabolite (Ac-5-ASA) at Steady State
Over a 24-hour period starting on day 7
CL of MMX Mesalamine Major Metabolite (Ac-5-ASA) at Steady State
Over a 24-hour period starting on day 7

Secondary Endpoints

Number of Participants With Clinical and Endoscopic Response During Double Blind Acute Phase at Week 8 Using Central Reading
Week 8
Number of Participants With Clinical and Endoscopic Response During Double Blind Acute Phase at Week 8 Using Local Reading
Week 8
Change From Baseline in Daily Ulcerative Colitis Scale (DUCS) Score During Double-Blind Acute Phase
Baseline to Week 8
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
MMX Mesalamine/Mesalazine (Low Dose)EXPERIMENTALOnce daily, tablets - the amount depends on the participants weight; 900 milligram per day (mg/day) for participants weighing 18 kg to less than or equal to (\<=) 23 kilograms (kg); 1200 mg/day for participants weighing greater than (\>) 23 kg to \<= 35 kg; 1800 mg/day for participants weighing \> 35 kg to \<= 50 kg; 2400 mg/day for participants weighing \> 50 kg to \<= 90 kg.
MMX Mesalamine/Mesalazine (High Dose)EXPERIMENTALOnce daily, tablets - the amount depends on the participants weight;1800 mg/day for participants weighing 18 kg to \<= 23 kg; 2400 mg/day for participants weighing \> 23 kg to \<= 35 kg; 3600 mg/day for participants weighing \> 35 kg to \<= 50 kg; 4800 mg/day for participants weighing \> 50 kg to \<= 90 kg.
SPD476 (1.2 g)EXPERIMENTAL -
SPD476 (2.4 g)EXPERIMENTAL -
SPD476 (4.8 g)EXPERIMENTAL -
PlaceboPLACEBO_COMPARATOR -
SPD476EXPERIMENTALMesalazine
AsacolACTIVE_COMPARATOR -
Mesalamine (Vanilla Yogurt)EXPERIMENTALOne 500mg capsule contents sprinkled onto 1 tablespoon of low-fat vanilla yogurt
Mesalamine (Applesauce)EXPERIMENTALOne 500mg capsule contents sprinkled onto 1 tablespoon of applesauce
Mesalamine (Dosing Cup)EXPERIMENTALOne 500mg capsule contents emptied into a dosing cup and taken with water
MMX Mesalamine (30mg/kg)EXPERIMENTAL -
MMX Mesalamine (60 mg/kg)EXPERIMENTAL -
MMX Mesalamine (100 mg/kg)EXPERIMENTAL -

Interventions

NameTypeDescription
MMX Mesalamine/Mesalazine (Low Dose)DRUGOnce daily, tablets - the amount depends on the participants weight; 900 milligram per day (mg/day) for participants weighing 18 kg to less than or equal to (\<=) 23 kilograms (kg); 1200 mg/day for participants weighing greater than (\>) 23 kg to \<= 35 kg; 1800 mg/day for participants weighing \> 35 kg to \<= 50 kg; 2400 mg/day for participants weighing \> 50 kg to \<= 90 kg.
MMX Mesalamine/Mesalazine (High Dose)DRUGOnce daily, tablets - the amount depends on the participants weight;1800 mg/day for participants weighing 18 kg to \<= 23 kg; 2400 mg/day for participants weighing \> 23 kg to \<= 35 kg; 3600 mg/day for participants weighing \> 35 kg to \<= 50 kg; 4800 mg/day for participants weighing \> 50 kg to \<= 90 kg.
SPD476, MMX™ mesalazine, 1.2g extended release tabletDRUGSPD476 1.2g administered Once Daily (QD)
SPD476, MMX™ mesalazine, 2.4g extended release tabletDRUGSPD476 2.4g administered Once Daily (QD)
SPD476, MMX™ mesalazine, 4.8g extended release tabletDRUGSPD476 4.8g administered Once Daily (QD)
PlaceboDRUGPlacebo administered Once Daily (QD)
SPD476 (1.2g)DRUG1.2g SPD476 once daily (QD) orally
SPD476 (2.4 g)DRUG2.4g SPD476 QD orally
SPD476 (4.8 g)DRUG4.8g SPD476 QD orally
SPD476DRUG2.4 g/day Once Daily (QD)
AsacolDRUG1.6g/day administered 800 mg Twice Daily (BID)
SPD476 (mesalazine)DRUG -
MesalamineDRUG -
MMX MesalamineDRUG30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
Unlock Study Design Details

Eligibility Criteria

Age Range5 Years to 17 Years
SexALL
Healthy VolunteersNo
Study Sites33

Inclusion Criteria: 1. Ability to voluntarily provide written, signed, and dated (personally or via a legally authorized representative \[LAR\]) informed consent or assent as applicable to participate in the study. 2. Subject's parent/LAR demonstrates an understanding, ability, and willingness to f...

Countries:United StatesCanadaHungaryIsraelPolandSlovakiaUnited KingdomBrazilFinlandGermanyItalyNetherlandsRomaniaSouth AfricaArgentinaAustraliaColombiaFranceIndiaNew ZealandSpainSwedenBelgiumChileCzechiaDenmarkMexicoPeruPortugalRussiaSingaporeSouth KoreaTaiwan
Unlock Eligibility Criteria

Frequently asked questions about Mesalamine

What is mesalamine?

Mesalamine is a small molecule drug candidate that Takeda Pharmaceutical Company Limited is developing. It is in Phase 1 clinical development, and the specific therapeutic indication has not been disclosed. Mesalamine is also known by the development code SHP429.

What does mesalamine target?

Mesalamine targets ALOX5, PTGS2, PTGS1, and PPARG. It is classified as an inhibitor of these targets. By acting on these molecular targets, mesalamine is designed to modulate the biological pathways associated with them.

Who is developing mesalamine?

Takeda Pharmaceutical Company Limited is developing mesalamine. Takeda trades under the ticker TAK. The company is responsible for the clinical development of this small molecule candidate.

What phase is mesalamine in?

Mesalamine is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 program includes one completed trial.

What clinical trials is mesalamine in?

Mesalamine has been studied in one completed Phase 1 trial, NCT02125292, titled Taste Assessment Study of SHP429 in Healthy Adult Subjects. The trial enrolled 18 healthy adult volunteers in the United States and was randomized and controlled.

Is mesalamine the same as SHP429?

Yes, mesalamine is also known by the development code SHP429. The two names refer to the same investigational drug candidate being developed by Takeda Pharmaceutical Company Limited.